Guidelines for antiretroviral therapy in adults

Southern African Journal of HIV Medicine

Volumn 13, Issue 3, 2012, Pages 114-133

  Meintjes, Graeme ^a   Maartens, Gary ^a   Boulle, Andrew ^a   Conradie, Francesca ^a   Goemaere, Eric ^a   Hefer, Eric ^a   Johnson, Dave ^a   Mathe, Moeketsi ^a   Moosa, Yunus ^a   Osih, Regina ^a   Rossouw, Theresa ^a   Van Cutsem, Gilles ^a   Variava, Ebrahim ^a   Venter, Francois ^a   Spencer, Dave ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CREATININE; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; HEPATITIS B SURFACE ANTIGEN; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PYRAZINAMIDE; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; BACTERIAL PNEUMONIA; BLOOD CELL COUNT; BONE DENSITY; BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; COHORT ANALYSIS; CONFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRYPTOCOCCAL MENINGITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSLIPIDEMIA; EVENING DOSAGE; FATTY LIVER; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HAIR LOSS; HEADACHE; HEPATITIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED NEUROMUSCULAR WEAKNESS SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERPIGMENTATION; KIDNEY FAILURE; LIFE EXPECTANCY; LIPOATROPHY; LONG TERM CARE; LOW DRUG DOSE; LUNG TUBERCULOSIS; MALARIA; MIXED INFECTION; MOOD DISORDER; MORBIDITY; MORTALITY; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEUROMUSCULAR DISEASE; OUTCOME ASSESSMENT; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PREGNANCY; PROTEINURIA; PSYCHOSIS; PURE RED CELL ANEMIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SOUTH AFRICA; TUBERCULOUS MENINGITIS; URINALYSIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; VIVID DREAM; WASTING SYNDROME;

EID: 84866911558     PISSN: 16089693     EISSN: 20786751     Source Type: Journal    
DOI: 10.4102/sajhivmed.v13i3.125     Document Type: Review

References (49)

1. Petersen ML, Wang Y, van der Laan MJ, Rhee SY, Shafer RW, Fessel WJ. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. AIDS 2007;21(12):1547-1554. [http://dx.doi.org/10.1097/QAD. 0b013e32825a69a8] (Pubitemid 47075475)
2. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363(3):257-265. [http://dx.doi.org/10.1056/NEJMoa0910370]
3. The CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011;171(17):1560-1569. [http://dx.doi.org/doi:10.1001/archinternmed.2011.401]
4. Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011;154(8):509-515. [http://dx.doi.org/10.1059/0003-4819-154-8-201104190- 00001]
5. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360(18):1815- 1826. [http://dx.doi.org/10.1056/NEJMoa0807252]
6. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009;373(9672):1352-1363. [http://dx.doi.org/10.1016/S0140-6736(09)60612-7]
7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365(6):493-505. [http://dx.doi.org/10.1056/NEJMoa1105243]
8. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int J Tuberc Lung Dis 2001;5(3):225-232. (Pubitemid 32397600)
9. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365(16):1492-1501. [http://dx.doi.org/10.1056/NEJMoa1014181]
10. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365(16):1471-1481. [http://dx.doi.org/10.1056/NEJMoa1013911]
11. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365(16):1482-1491. [http://dx.doi.org/10.1056/NEJMoa1013607]
12. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV) - associated tuberculous meningitis. Clin Infect Dis 2011;52(11):1374-1383. [http://dx.doi.org/10.1093/ cid/cir230]
13. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010;50(11):1532-1538. [http://dx.doi.org/10.1086/652652]
14. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS One 2009;4(5):e5575. [http://dx.doi.org/10.1371/journal.pone.0005575]
15. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358(20):2095-2106. [http://dx.doi.org/10.1056/NEJMoa074609] (Pubitemid 351679596)
16. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361(23):2230-2240. [http://dx.doi.org/10.1056/NEJMoa0906768]
17. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55(1):49-57. [http://dx.doi.org/10.1097/QAI.0b013e3181dd911e]
18. Tan DH, Chan K, Raboud J, et al. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr 2011;58(1):38-46. [http://dx.doi.org/10. 1097/QAI.0b013e3182282cfc]
19. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011;52(7):929-940. [http://dx.doi.org/10.1093/cid/ciq244]
20. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371(9622):1417-1426. [http://dx.doi.org/10.1016/S0140-6736(08)60423-7]
21. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011;25(16):1993-2004. [http://dx.doi.org/10.1097/QAD. 0b013e328349c6ee]
22. Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis 2011;53(12):1283-1290. [http://dx.doi.org/10.1093/cid/cir729]
23. Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira T. Primary drug resistance in South Africa: data from 10 years of surveys. AIDS Res Hum Retroviruses 2012;28(6):558-665. [http://dx.doi.org/10.1089/AID.2011.0284]
24. Smith CJ, Sabin CA, Lampe FC, et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 2003;17(7):963-969. [http://dx.doi.org/10.1097/01. aids.0000060352.78202.79] (Pubitemid 36549707)
25. Guihot A, Tubiana R, Breton G, et al. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 2010;24(4):614-617.
26. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005;41(3):361-372. [http://dx.doi.org/10.1086/431484] (Pubitemid 41022115)
27. Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007;370(9585):407-413. [http://dx.doi.org/10.1016/S0140-6736(07)60948-9] (Pubitemid 47176633)
28. Tuboi SH, Pacheco AG, Harrison LH, et al. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr 2010; 53(1):70-77. [http://dx.doi.org/10.1097/QAI. 0b013e3181c22d19]
29. Loutfy MR, Genebat M, Moore D, et al. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr 2010;55(4):451-459.
30. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004;364(9428):51-62. [http://dx.doi.org/10.1016/S0140-6736(04)16589-6]
31. Hamers R, Sigaloff K, Wallis C, et al. Patterns of HIV-1 Drug-Resistance after First-line ART Failure and Response to Second-line ART in a Multi-country Cohort: Sub-Saharan Africa. 19th Conference on Retroviruses and opportunistic Infections. Seattle, 5 - 8 March 2012.
32. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011;365(7):637-646. [http://dx.doi.org/10.1056/ NEJMra1004180]
33. Davies G, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007;(4):CD005159.
34. Bradshaw D, Chopra M, Kerber K, et al. Every death counts: use of mortality audit data for decision making to save the lives of mothers, babies, and children in South Africa. Lancet 2008;371(9620):1294-1304. [http://dx.doi.org/10.1016/S0140-6736(08)60564-4]
35. Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011;25(18):2301-2304. [http://dx.doi.org/10.1097/QAD.0b013e32834cdb71]
36. World Health Organization. Use of efavirenz during pregnancy: A public health perspective. Geneva: WHO, 2012. http://www.who.int/hiv/pub/treatment2/ efavirenz/en/index.html (1 July 2012).
37. Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005;19(3):221-240. (Pubitemid 40396554)
38. Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007;7(11):733-738. [http://dx.doi.org/10.1016/S1473-3099(07)70262-1] (Pubitemid 47600092)
39. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010;10(11):791-802. [http://dx.doi.org/10.1016/S1473-3099(10)70170-5]
40. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008;8(8):516-523. [http://dx.doi.org/10.1016/S1473-3099(08)70184-1] (Pubitemid 352005824)
41. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010;24(15):2381-2390. [http://dx.doi.org/10.1097/QAD.0b013e32833dfc68]
42. Meintjes G, Scriven J, Marais S. Management of the Immune Reconstitution Inflammatory Syndrome. Curr HIV/AIDS Rep 2012;9(3):238-250. [http://dx.doi.org/ 10.1007/s11904-012-0129-5]
43. Meintjes G, Sonderup MW. A practical approach to the diagnosis and management of paradoxical tuberculosis immune reconstitution inflammatory syndrome. Continuing Medical Education 2011;29(10):410-417.
44. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009;49(9):1441-1449. [http://dx.doi.org/10.1086/630210]
45. Arasteh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther 2009;14(6):859-864. [http://dx.doi.org/10.3851/1301]
46. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010;50(4):605-612. [http://dx.doi.org/10.1086/650002]
47. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):29-38. [http://dx.doi.org/10.1016/S0140-6736(07)61047-2] (Pubitemid 47017466)
48. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370(9581):39-48. [http://dx.doi.org/10.1016/S0140-6736(07)61048-4] (Pubitemid 47017467)
49. Stevens WS, Wallis CL, Sanne I, Venter F. Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa? J Acquir Immune Defic Syndr 2009;52(5):655-656. [http://dx.doi.org/10.1097/QAI.0b013e3181ba1b00]